Patent US4828828A successfully refreshed from Google Patents.
US4828828A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of treating degenerative joint disease by injection of meth(acrylamide) (co)-polymers
Assignee: Individual
•
Filing: 1987-07-28
•
Granted: 1989-05-09
•
Expires: 2007-07-28
Abstract
Abstract A method for the treatment of degenerative joint disease in a mammal suffering therefrom which includes administration by injection of an effective amount of a pharmaceutical composition into the arthritically afflicted joints of the mammal thereby lubricating and cushioning the joints. The composition includes acrylamide or methacrylamide polymers or copolymers thereof having a molecular weight from about 1 to about 15 million and a pharmaceutically acceptable diluent.
Inventors
- 👤 Seymour F. Trager
- 👤 Victoria S. Chylinski
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-30 02:39
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/74; A61K31/785
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
74 words
A method for the treatment of degenerative joint disease in a mammal suffering therefrom comprising administration by injection into the afflicted joints of said mammal of an effective amount of a pharmaceutical composition which comprises from about 2 to about 5 percent by weight acrylamide or methacrylamide polymers or copolymers thereof having a molecular weight from about 1 to about 15 million and a pharmaceutically acceptable diluent therefor, thereby lubricating and cushioning said joints.
Claim 2
Independent Claim
74 words
A method for the treatment of degenerative joint disease in a mammal suffering therefrom comprising administration by injection into the afflicted joints of said mammal of an effective amount of a pharmaceutical composition which comprises from about 2 to about 5 percent by weight acrylamide or methacrylamide polymers or copolymers thereof having a molecular weight from about 1 to about 15 million and a pharmaceutically acceptable diluent therefor, thereby lubricating and cushioning said joints.
Claim 3
Dependent Claim
28 words
A method of claim 1, wherein said polymers or copolymers are present in an amount between about 3.5 to about 5 percent by weight of said pharmaceutical composition.
Claim 4
Dependent Claim
25 words
A method of claim 1, wherein said polymers or copolymers are present in an amount of about 4 percent by weight of said pharmaceutical composition.
Claim 5
Dependent Claim
10 words
A method of claim 1, wherein said polymer is polyacrylamide.
Claim 6
Dependent Claim
23 words
A method of claim 1, wherein said pharmaceutical composition has a Brookfield viscosity of about 30,000 to about 125,000 cps at 25° C.
Claim 7
Dependent Claim
13 words
A method of claim 1, wherein said pharmaceutical composition further contains an antibiotic.
Claim 8
Dependent Claim
14 words
A method of claim 1, wherein said pharmaceutical composition further contains an anti-inflammatory agent.
Claim 9
Dependent Claim
12 words
A method of claim 7, wherein said anti-inflammatory agent is 6-methylprednisolone 21-acetate.
Claim 10
Dependent Claim
21 words
A method of claim 1 wherein said pharmaceutical composition is administered in a dose from about 0.2 to about 5 ml.
Claim 11
Dependent Claim
82 words
A method of claim 1, wherein said pharmaceutical composition comprises (a) 2 to 5 percent by weight acrylamide or methacrylamide polymers or copolymers; (b) 0.4 to 8.6 percent by weight sodium chloride; (c) 0.075 to 0.3 percent by weight potassium chloride; (d) 0.04 to 0.33 percent by weight calcium chloride; (e) 0.02 to 0.04 percent by weight magnesium chloride hexahydrate; (f) 0.3 to 0.4 percent by weight sodium acetate; (g) 0.15 to 0.20 percent by weight buffering agent; and (h) remainder water.
Claim 12
Dependent Claim
13 words
A method of claim 10 wherein said buffering agent is sodium citrate dihydrate.
Claim 13
Dependent Claim
59 words
A method of claim 1, wherein said pharmaceutical composition comprises about 4 percent by weight of said polymer having a molecular weight of about 5 million, about 0.49 percent by weight sodium chloride, about 0.075 percent by weight potassium chloride, about 0.048 percent by weight calcium chloride, about 0.03 percent by weight sodium citrate dihydrate and the remainder water.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-05-08 | 1992-11-07 | 1993-05-09 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-05-08 | 1996-11-07 | 1997-05-09 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-05-08 | 2000-11-07 | 2001-05-09 | $7700.00 | Window Closed / Lapsed |